DAB.bio launches first lab tool for continuous in-situ liquid-liquid extraction

Delft, the Netherlands, 20 June 2024 - DAB.bio today launches ISPRIN, its first product for continuous in-situ liquid-liquid extraction for the lab, to provide researchers a tool to start the interactive strain and process development process towards a successful scale-up. ISPRIN complements the offering of DAB.bio by enabling lab-scale R&D using continuous in-situ liquid-liquid extraction with a clear outlook on scaling with the patented FAST™ platform technology.ISPRIN is an off-the-shelf tool designed to make continuous in-situ liquid-liquid extraction easy and accessible for use in lab-scale research and development. ISPRIN allows researchers to assess whether the selective removal of process-limiting compounds through ISPR enables titer improvements and a reduction in emulsion-forming conditions. The use of ISPRIN translates into a higher extraction capacity, prolonged fermentations, and higher volumetric productivity. In a case study on the production of an aromatic alcohol, the use of ISPRIN showed that continuous in-situ liquid-liquid extraction facilitates a 10x increase in accumulated product, thereby providing a cost-competitive industrial outlook.ISPRIN provides a stepping stone for researchers to start working with continuous in-situ liquid-liquid extraction in the lab and establishes the technology as an industry standard method towards cost-effective biomanufacturing of planet-friendly chemicals by providing a clear outlook on scaling with the patented FAST™ platform technology. ISPRIN is available to researchers everywhere through the DAB.bio website.About DAB.bioDAB.bio is revolutionizing industrial biomanufacturing with its FAST™ platform technology. FAST™ combines fermentation with continuous product recovery to deliver the most efficient and cost-effective biomanufacturing platform. A spin out from Delft University of Technology, DAB.bio offers patented technology licensing and fermentation/process development services. Following nearly 10 years of R&D, DAB.bio’s scalable solutions significantly lower biomanufacturing costs, enabling the cost-effective production of biorenewables. DAB.bio aims to accelerate the bioeconomy towards a net-zero future.